Structured evidence table for Saffron Mood Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Saffron Mood Meta-Analysis | However, due to some potentially significant adverse events associated with its medicinal use at higher doses or prolonged administration, clinical monitoring should be considered. | 1 | Hasheminasab FS (2026) | Adverse Events of Saffron (<i>Crocus sativus</i> L.): Systematic Review of Current Evidence. |
| Saffron Mood Meta-Analysis | Background Crocus sativus L., commonly known as saffron, is a widely used spice with a rich history of culinary and medicinal applications. | 1 | Hasheminasab FS (2026) | Adverse Events of Saffron (<i>Crocus sativus</i> L.): Systematic Review of Current Evidence. |
| Saffron Mood Meta-Analysis | This systematic review aims to compile human data from studies on monopreparations of C. | 1 | Hasheminasab FS (2026) | Adverse Events of Saffron (<i>Crocus sativus</i> L.): Systematic Review of Current Evidence. |
| Saffron Mood Meta-Analysis | This literature review synthesises evidence from randomised controlled trials, meta-analyses, safety data, dosing patterns, proposed mechanisms, and guideline positioning regarding saffron in depression, with a focus on adult major depressive disorder and related depressive symptomatology. | 4 | Dimech L (2026) | The Role of Saffron in the Treatment of Depression: A Literature Review. |
| Saffron Mood Meta-Analysis | Across placebo-controlled trials in mild-to-moderate depression, saffron, most commonly administered at 30 mg per day for approximately six weeks, has been associated with clinically meaningful reductions in depressive symptom severity, typically measured using the Hamilton Depression Rating Scale (HAM-D). | 4 | Dimech L (2026) | The Role of Saffron in the Treatment of Depression: A Literature Review. |
| Saffron Mood Meta-Analysis | Meta-analytic evidence generally indicates superiority over placebo and similar efficacy to selective serotonin reuptake inhibitors (SSRIs), with an overall favourable short-term tolerability profile; however, confidence is constrained by small sample sizes, restricted settings, variable product standardisation (including stigma versus petal preparations), and risk of bias/publication bias. | 4 | Dimech L (2026) | The Role of Saffron in the Treatment of Depression: A Literature Review. |
| Saffron Mood Meta-Analysis | Saffron ( Crocus sativus L.) has attracted increasing interest as a nutraceutical option for depressive disorders, particularly for patients who experience incomplete response or poor tolerability with conventional treatments. | 4 | Dimech L (2026) | The Role of Saffron in the Treatment of Depression: A Literature Review. |
Source documents